Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

NCT06682169 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

182

Enrollment

INDUSTRY

Sponsor class

Conditions

Graft-versus-host Disease

Interventions

DRUG: Rovadicitinib
DRUG: Imatinib
DRUG: Methotrexate
DRUG: Mycophenolate mofetil
DRUG: Rituximab

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.